Pharvaris (PHVS) Other Non Operating Income (2020 - 2025)
Pharvaris (PHVS) reported Other Non Operating Income of -$25.9 million for Q4 2025, down 556.3% on a YoY basis from $5.7 million in Q4 2024, and up 100.0% quarter-over-quarter from -$14030.4 billion in Q3 2025.
Pharvaris (PHVS) Other Non Operating Income (2020 - 2025) Analysis & Trends
Pharvaris has reported Other Non Operating Income for 6 years, with the latest figure at -$25.9 million in Q4 2025.
- For the quarter ending Q4 2025, Other Non Operating Income fell 556.3% year-over-year to -$25.9 million; the trailing twelve-month figure through Dec 2025 stood at -$445.2 billion (down 763.21% YoY), and the FY2025 full-year result was -$11.6 million, down 235.98% from the prior year.
- Other Non Operating Income for Q4 2025 stood at -$25.9 million, up from -$14030.4 billion in the prior quarter.
- The five-year high for Other Non Operating Income was $13585.2 billion in Q2 2025, with the low at -$14030.4 billion in Q3 2025.
- Historically, Other Non Operating Income has averaged -$18.9 billion across 5 years, with a median of -$348315.8 in 2023.
- The largest YoY upside for Other Non Operating Income was 118111358.39% in 2024 against a maximum downside of 302291875.29% in 2024.
- Pharvaris' Other Non Operating Income stood at $22.4 million in 2021, then soared by 71.08% to $38.4 million in 2022, then tumbled by 103.81% to -$1.5 million in 2023, then surged by 488.39% to $5.7 million in 2024, then tumbled by 556.3% to -$25.9 million in 2025.
- The last three Other Non Operating Income figures came in at -$25.9 million (Q4 2025), -$14030.4 billion (Q3 2025), and $13585.2 billion (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Pharvaris | 28.66 Bn | 28.37 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -25.88 Mn |
| Sep 30, 2025 | -14,030.42 Bn |
| Jun 30, 2025 | 13,585.23 Bn |
| Mar 31, 2025 | 5.67 Mn |
| Dec 31, 2024 | 5.67 Mn |
| Sep 30, 2024 | 3,455.58 Bn |
| Jun 30, 2024 | -3,388.46 Bn |
| Mar 31, 2024 | -587,995.48 |
| Dec 31, 2023 | -1.46 Mn |
| Sep 30, 2023 | -2.93 Mn |
| Jun 30, 2023 | 1.12 Mn |
| Mar 31, 2023 | -108,636.15 |
| Dec 31, 2022 | 38.35 Mn |
| Sep 30, 2022 | -11.62 Mn |
| Jun 30, 2022 | -16.02 Mn |
| Mar 31, 2022 | 45,242.56 |
| Dec 31, 2021 | 22.42 Mn |
| Sep 30, 2021 | 5.02 Mn |
| Jun 30, 2021 | -2.98 Mn |
| Mar 31, 2021 | -7.12 Mn |